BioLineRx announced that hematopoietic stem cells mobilized by BL-8040 in combination with granulocyte colony-stimulating factor were successfully engrafted in all 11 patients participating in the Part 1, lead-in period of the GENESIS trial, a double-blind, placebo-controlled Phase 3 trial comparing BL-8040 and G-CSF to G-CSF alone, in mobilization of HSCs for autologous transplantation in multiple myeloma patients. These data follow previously announced successful mobilization data which led the Data Monitoring Committee to recommend proceeding to the randomized placebo-controlled Part 2 of the study.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.